- Home
- DSY vs CRDL Comparison
DSY vs CRDL Comparison
Compare DSY & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- CRDL
- Stock Information
- Founded
- DSY 2020
- CRDL 2017
- Country
- DSY China
- CRDL Canada
- Employees
- DSY N/A
- CRDL N/A
- Industry
- DSY
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DSY
- CRDL Health Care
- Exchange
- DSY Nasdaq
- CRDL Nasdaq
- Market Cap
- DSY 77.6M
- CRDL 80.1M
- IPO Year
- DSY N/A
- CRDL N/A
- Fundamental
- Price
- DSY $1.29
- CRDL $1.24
- Analyst Decision
- DSY
- CRDL Strong Buy
- Analyst Count
- DSY 0
- CRDL 3
- Target Price
- DSY N/A
- CRDL $9.33
- AVG Volume (30 Days)
- DSY 11.3K
- CRDL 250.7K
- Earning Date
- DSY 02-10-2025
- CRDL 08-11-2025
- Dividend Yield
- DSY N/A
- CRDL N/A
- EPS Growth
- DSY 120.37
- CRDL N/A
- EPS
- DSY 0.01
- CRDL N/A
- Revenue
- DSY $7,323,356.00
- CRDL N/A
- Revenue This Year
- DSY N/A
- CRDL N/A
- Revenue Next Year
- DSY N/A
- CRDL N/A
- P/E Ratio
- DSY $102.83
- CRDL N/A
- Revenue Growth
- DSY 16.37
- CRDL N/A
- 52 Week Low
- DSY $0.75
- CRDL $0.77
- 52 Week High
- DSY $6.98
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- DSY 42.27
- CRDL 45.66
- Support Level
- DSY $1.27
- CRDL $1.35
- Resistance Level
- DSY $1.39
- CRDL $1.50
- Average True Range (ATR)
- DSY 0.07
- CRDL 0.10
- MACD
- DSY -0.00
- CRDL -0.02
- Stochastic Oscillator
- DSY 45.28
- CRDL 18.50
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.